Popular search terms:
Search Results Label
44 results found-
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/seqirus-real-world-evidence-published -
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
https://www.seqirus.us/news/seqirus-ships-2020-2021-influenza-vaccines-to-us-market -
Seqirus | Latest News
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news -
Seqirus | A World Leader in Influenza Vaccines
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.seqirus.us/ -
Seqirus | Partnership Opportunities
Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.seqirus.us/partnering -
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
https://www.seqirus.us/news/seqirus-receives-fda-approval-for-fluad-quadrivalent-for-adults-65-years-and-older -
Seqirus Announces US FDA Approval of Pandemic Influenza Vaccine
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine -
New Clinical Data Reinforces the Ability of MF59 Adjuvanted Seasonal and Pandemic Influenza Vaccines
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
https://www.seqirus.us/news/new-clinical-data-reinforces-the-ability-of-mf59-adjuvanted-seasonal-and-pandemic-influenza-vaccines -
Seqirus | About Us
Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.seqirus.us/our-company -
Seqirus Releases First Shipment for 2019 2020 Season
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.
https://www.seqirus.us/news/seqirus-releases-first-shipment-for-2019-2020-season